Attempts to produce a vaccine to protect against Chlamydia trachomatis-induced trachoma were initiated more than 100 years ago and continued for several decades. Using whole organisms, protective responses were obtained. However, upon exposure to C. trachomatis, disease exacerbation developed in some immunized individuals, precluding the implementation of the vaccine. Evidence of the role of C. trachomatis as a sexually transmitted pathogen started to emerge in the 1960s, and it soon became evident that it can cause acute infections and long-term sequelae in women, men, and newborns. The main focus of this minireview is to summarize recent findings and discuss formulations, including antigens, adjuvants, routes, and delivery systems for immunization, primarily explored in the female mouse model, with the goal of implementing a vaccine against C. trachomatis genital infections.
Keyphrases
- mouse model
- drug induced
- chronic obstructive pulmonary disease
- primary care
- pregnant women
- quality improvement
- liver failure
- healthcare
- respiratory failure
- polycystic ovary syndrome
- high glucose
- diabetic rats
- type diabetes
- dendritic cells
- oxidative stress
- metabolic syndrome
- gram negative
- insulin resistance
- extracorporeal membrane oxygenation
- preterm infants
- gestational age
- acute respiratory distress syndrome
- aortic dissection